ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Order Full text via Infotrieve
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Molema, J
Right arrow Articles by Folgering, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Molema, J
Right arrow Articles by Folgering, H.
Eur Respir J 1989; 2: 308-316
Copyright © ERS Journals Ltd 1989

Clinical Trial

Effects of long-term treatment with inhaled cromoglycate and budesonide on bronchial hyperresponsiveness in patients with allergic asthma

J Molema, CL van Herwaarden, and HT Folgering

Twenty two allergic patients with bronchial asthma completed this study. Effects of long-term treatment with inhaled cromoglycate 4 x 2 mg.day-1 were compared to the effects of inhaled budesonide 4 x 0.1 mg.day-1 on symptoms, additional beta 2-agonist use, lung function and bronchial hyperresponsiveness measured by the provocation concentration of histamine producing a 20% fall in forced expiratory volume in one second (FEV1) (PC20 histamine) and exercise-induced fall in FEV1. The study was carried out in a double-blind way with a randomized crossover design using a double-dummy technique. After a single-blind placebo period, the two active treatment periods of 6 weeks were separated by a single-blind placebo period. Symptom score and beta 2-agonist use decreased during both active treatment periods, which showed no mutual differences. Morning and evening peak expiratory flow rates were significantly higher during treatment with budesonide versus placebo (p less than 0.01 and p less than 0.001), and also versus cromoglycate (p less than 0.02 and p less than 0.05). FEV1 showed improvement after a 6 week treatment with budesonide versus placebo (p less than 0.05), although there was no significant difference between the two active treatments. PC20 histamine did not change during treatment with cromoglycate. Budesonide showed a significant increase in PC20 histamine versus placebo (p less than 0.05) and was marginally significantly better than cromoglycate (p = 0.05). Exercise-induced fall in FEV1 was not changed by cromoglycate, but improved significantly during budesonide in comparison with placebo (p less than 0.01) and also with cromoglycate (p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
 Eur Respir JHome page
B. Dahlen, P.M. O'Byrne, R.M. Watson, A. Roquet, F. Larsen, and M.D. Inman
The reproducibility and sample size requirements of exercise-induced bronchoconstriction measurements
Eur. Respir. J., April 1, 2001; 17(4): 581 - 588.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
Adjuvant therapy
Can. Med. Assoc. J., November 1, 1999; 161(90111): s35 - 39.
[Full Text]

Home page
 ThoraxHome page
P M van Grunsven, C P van Schayck, J Molema, R P Akkermans, and C van Weel
Effect of inhaled corticosteroids on bronchial responsiveness in patients with "corticosteroid naive" mild asthma: a meta-analysis
Thorax, April 1, 1999; 54(4): 316 - 322.
[Abstract] [Full Text]

Home page
 NEJMHome page
M. Weinberger and L. Hendeles
Theophylline in Asthma
N. Engl. J. Med., May 23, 1996; 334(21): 1380 - 1388.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the European Respiratory Society.